Home/Filings/4/A/0000921895-22-001874
4/A//SEC Filing

Javitt Jonathan C 4/A

Accession 0000921895-22-001874

CIK 0001719406other

Filed

Jun 1, 8:00 PM ET

Accepted

Jun 2, 9:46 AM ET

Size

6.7 KB

Accession

0000921895-22-001874

Insider Transaction Report

Form 4/AAmended
Period: 2022-06-01
Javitt Jonathan C
DirectorChairman and Chief Scientist10% Owner
Transactions
  • Purchase

    Common Stock

    2022-06-01$0.58/sh+100,000$58,000146,332 total
Holdings
  • Common Stock

    (indirect: By Trust)
    1,422,000
  • Common Stock

    (indirect: By Trust)
    13,299,997
Footnotes (3)
  • [F1]Reflects charitable donations of 49,000 shares of Common Stock that occurred in December 2021.
  • [F2]Held by the Jonathan Javitt Living Trust of which the Reporting Person is trustee.
  • [F3]Held by The Javitt 2012 Irrevocable Dynasty Trust of which the Reporting Person is the Grantor.

Issuer

NRX Pharmaceuticals, Inc.

CIK 0001719406

Entity typeother

Related Parties

1
  • filerCIK 0001303782

Filing Metadata

Form type
4/A
Filed
Jun 1, 8:00 PM ET
Accepted
Jun 2, 9:46 AM ET
Size
6.7 KB